How The RxSight (RXST) Narrative Is Shifting After 2026 Guidance And Target Resets

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide.

RxSight’s modeled fair value is steady at US$9.93, closely tracking analyst price targets that cluster in the US$9 to US$10 range. Bullish and bearish commentary around the new 2026 revenue outlook, recent target cuts to the high single digits, and a mix of Neutral and Hold ratings all help explain why that target band has stayed tight rather than moving sharply in either direction. As you read on, you will see how these shifting views and model tweaks can help you follow the evolving story around RxSight’s stock.

Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value RxSight.

What Wall Street Has Been Saying

🐂 Bullish Takeaways

UBS lifted its price target to US$9 from US$8 and kept a Neutral rating, signaling that the updated 2026 outlook is viewed as helping to limit downside risk rather than opening up fresh concerns. Analysts at UBS and Piper Sandler are aligned around a valuation range close to US$9 to US$10, which supports the idea that RxSight’s current fundamentals and execution keep it within a relatively stable band in their models.

🐻 Bearish Takeaways

Piper Sandler cut its target to US$10 from US$11 after RxSight issued 2026 revenue guidance of US$120m to US$135m, which the firm notes is below prior estimates, pointing to more tempered growth expectations in its coverage. Stifel lowered its target to US$9 from US$10 and maintained a Hold rating, reflecting more cautious assumptions as it refreshed models across the medical technology and supplies group rather than a clear directional call on strong upside.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!NasdaqGM:RXST 1-Year Stock Price Chart

We've flagged 2 risks for RxSight. See which could impact your investment.

How This Changes the Fair Value For RxSight

Fair Value: Model fair value is unchanged at US$9.93, aligned with price targets around US$9 to US$10. Revenue Growth: Revenue growth input is effectively unchanged at 5.22%. Net Profit Margin: Net profit margin assumption is now 12.79%, compared with 12.70% previously. P/E Ratio: Future P/E multiple is now 26.74x, compared with 26.93x previously. Discount Rate: Discount rate is now 7.85%, compared with 7.86% previously.

Never Miss an Update: Follow The Narrative

Narratives connect a company’s business story to a financial forecast and fair value, so you can see how new information feeds into the bigger picture. They refresh as catalysts and risks are updated, giving you a living summary rather than a one-off report.

Story Continues

Head over to the Simply Wall St Community and follow the Narrative on RxSight to stay up to date on:

How realignment of sales, clinical support, and customer success teams, plus new education and marketing efforts, are aimed at lifting adoption and utilization of light adjustable lenses. What international expansion into newly approved European and Asian markets could mean for future revenue streams as cataract procedures and demand for vision correction increase globally. Key risks around heavy reliance on a single product, rising SG&A and R&D costs, regulatory hurdles in major markets, and reimbursement and pricing pressure in cataract surgery.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include RXST.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments